Innovent Biologics, Inc. (HKG: 1801) announced first patient dosing in the pivotal Phase 3 HeriCare-Breast01 study (NCT07377643) evaluating IBI354, its HER2-targeting antibody-drug conjugate (ADC), as first-line treatment for unresectable locally advanced or metastatic HER2-positive breast cancer. The multicenter, randomized, open-label trial positions IBI354—with its high drug-to-antibody ratio (DAR 8) and “high potency, low toxicity” profile—to challenge the current standard-of-care THP regimen (paclitaxel + trastuzumab + pertuzumab).
NMPA NDA submission; global partnership discussions
2028
Commercial
China launch; potential US/EU development
2028+
Forward‑Looking Statements This brief contains forward‑looking statements regarding IBI354 clinical development in HER2+ breast cancer, HeriCare study outcomes, and Innovent Biologics’ ADC commercialization strategy. Actual results may differ due to Phase 3 trial execution, competitive dynamics with trastuzumab deruxtecan, and biosimilar trastuzumab/pertuzumab pricing pressure.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
